Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 68 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others

ORIGINAL ARTICLE

Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes

Ramteke Karuna Balwant, Ramanand Sunita Jaiprakash, Ramanand Jaiprakash B, Jain Suyog Subhash, Raparti Girish Tulsidas, Patwardhan Milind Hari, Murthy Mangala, Ghanghas Ravi G

Year : 2011| Volume: 15| Issue : 5 | Page no: 33-39

   This article has been cited by
 
1 The effect of dopamine agonists on metabolic variables in adults with type 2 diabetes: A systematic review with meta analysis and trial sequential analysis of randomized clinical trials
Ida Brandt Andersen,Mikkel Andreassen,Jesper Krogh
Diabetes, Obesity and Metabolism. 2020;
[Pubmed]  [Google Scholar] [DOI]
2 Bromocriptine mesylate improves glucose tolerance and disposal in a high-fat-fed canine model
Mary Courtney Moore,Marta S. Smith,Larry L. Swift,Anthony H. Cincotta,Michael Ezrokhi,Nicholas Cominos,Yahong Zhang,Ben Farmer,Alan D. Cherrington
American Journal of Physiology-Endocrinology and Metabolism. 2020; 319(1): E133
[Pubmed]  [Google Scholar] [DOI]
3 Late phase completed clinical trials investigating bromocriptine mesylate quick release as treatment of type 2 diabetes mellitus
Maka Siamashvili,Stephen Davis
Expert Opinion on Pharmacotherapy. 2020; : 1
[Pubmed]  [Google Scholar] [DOI]
4 Evidence-based practice use of quick-release bromocriptine across the natural history of type 2 diabetes mellitus
Stanley S. Schwartz,Farhad Zangeneh
Postgraduate Medicine. 2016; : 1
[Pubmed]  [Google Scholar] [DOI]
5 A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters
E.M. Lamos,D.L. Levitt,K.M. Munir
Primary Care Diabetes. 2016; 10(1): 60
[Pubmed]  [Google Scholar] [DOI]
6 Brain signaling systems in the Type 2 diabetes and metabolic syndrome: promising target to treat and prevent these diseases
Alexander O Shpakov,Kira V Derkach,Lev M Berstein
Future Science OA. 2015; 1(3)
[Pubmed]  [Google Scholar] [DOI]
7 Bromocriptine mesylate QR in treatment of Type 2 diabetes
George Grunberger
Diabetes Management. 2014; 4(2): 203
[Pubmed]  [Google Scholar] [DOI]
8 A review of the efficacy and safety of oral antidiabetic drugs
Stephanie Aleskow Stein,Elizabeth Mary Lamos,Stephen N Davis
Expert Opinion on Drug Safety. 2013; 12(2): 153
[Pubmed]  [Google Scholar] [DOI]

 

Read this article